Bijan Salari
Urology · Hyannis, MANPI 1861886681
Payments from drug & device makers
What this record shows
The money is spread across several categories — food and beverage (39.0%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 34 manufacturers reported payments, led by Intuitive Surgical at 29.5% of the total. Reporting peaked in 2024 at $4,750 and has fallen 77.3% since, to $1,080 in 2025.
Across 159 payments — averaging $87.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Teleflex LLC$3K
- Boston Scientific$2K
- Medtronic$1K
- Johnson & Johnson$808
- Axonics, Inc.$520
- plus $2K from 28 others
What the payments were for
- Speaking & faculty fees$4,01529%
- Travel & lodging$3,74227%
- Food & beverage$5,41739%
- Education$6114%
- Gifts$1041%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 3 | $4,104 |
| Teleflex LLC | 26 | $3,281 |
| Boston Scientific | 12 | $1,727 |
| Medtronic | 14 | $1,175 |
| Johnson & Johnson(3 entities) | 15 | $808 |
| Axonics, Inc. | 10 | $520 |
| AbbVie(2 entities) | 11 | $405 |
| Astellas Pharma US Inc | 11 | $327 |
| Urogen Pharma, Inc. | 4 | $258 |
| Pfizer | 8 | $130 |
| Bayer | 1 | $124 |
| Olympus America Inc. | 1 | $112 |
| Tolmar, Inc. | 4 | $94 |
| Coloplast | 1 | $90 |
| Myovant Sciences Inc. | 4 | $90 |
| Endo Pharmaceuticals Inc. | 5 | $83 |
| Urovant Sciences Inc | 5 | $82 |
| Sumitomo Pharma America, Inc. | 4 | $79 |
| Progenics Pharmaceuticals, Inc. | 2 | $54 |
| Acerus Pharmaceuticals Corporation | 3 | $45 |
| Merck | 2 | $37 |
| AstraZeneca | 1 | $35 |
| Laborie Medical Technologies Corp. | 1 | $30 |
| Tolmar Pharmaceuticals, Inc. | 1 | $24 |
| Halozyme Inc | 1 | $23 |
| Amgen | 1 | $21 |
| Myriad Genetic Laboratories, Inc. | 1 | $19 |
| Rochester Medical Corporation | 1 | $18 |
| Cook Medical LLC | 1 | $17 |
| 180 Medical, Inc. | 1 | $16 |
| Calyxo, Inc. | 1 | $16 |
| E.r. Squibb & Sons, L.L.C. | 1 | $15 |
| BD | 1 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Da Vinci Surgical System$4,000
- UroLift$2,759
- AMS 700$1,152
- INTERSTIM$834
- Axonics r-SNM System$300
- Erleada$239
- BOTOX$125
- Nubeqa$124
- ZUSDURI$121
- AKEEGA$114
- iTIND System$112
How this compares
$13,889 in reported general payments places this provider in the 85th percentile of 327 urology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| ErleadaApalutamide | 11 | $162,985 |
| GemtesaVibegron | 39 | $27,204 |
| MyrbetriqMirabegron | 20 | $12,169 |
| Tamsulosin Hcl | 236 | $3,065 |
| Cephalexin | 98 | $1,538 |
| Oxybutynin Chloride ErOxybutynin Chloride | 63 | $1,509 |
| Methenamine Hippurate | 13 | $1,171 |
| Estradiol | 12 | $1,061 |
| Finasteride | 23 | $226 |
| Clotrimazole-BetamethasoneClotrimazole/Betamethasone Dip | 11 | $137 |
| Ciprofloxacin Hcl | 33 | $111 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 22 | $71 |
| Tramadol Hcl | 37 | $22 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonErleada | $808 | $162,98511 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $79 | $27,20439 claims |
| Astellas Pharma US IncMyrbetriq | $327 | $12,16920 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 327 urology providers in Massachusetts.
Other urology in Hyannis
- Andrew KramerHyannis$108K
- Brian KowalHyannis$24K
- Christopher CutieBoston$3.5M
- Brian EisnerBoston$424K
- David StaskinBrighton$407K
- Liam HurleyNorth Andover$319K
- Stephen DretlerBoston$298K
- Abraham MorgentalerChestnut Hill$290K
- Louis LiouCambridge$278K
- Tony LuongoBoston$265K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.